Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
4.200
-0.330 (-7.28%)
At close: May 30, 2025, 4:00 PM
4.170
-0.030 (-0.71%)
After-hours: May 30, 2025, 6:54 PM EDT
Karyopharm Therapeutics Employees
Karyopharm Therapeutics had 279 employees as of December 31, 2024. The number of employees decreased by 46 or -14.15% compared to the previous year.
Employees
279
Change (1Y)
-46
Growth (1Y)
-14.15%
Revenue / Employee
$509,412
Profits / Employee
-$224,093
Market Cap
36.29M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
KPTI News
- 12 days ago - Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference - PRNewsWire
- 17 days ago - Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting - PRNewsWire
- 17 days ago - These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results - Benzinga
- 18 days ago - Karyopharm Therapeutics Inc. (KPTI) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 18 days ago - Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification - PRNewsWire
- 22 days ago - Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025 - PRNewsWire
- 4 weeks ago - Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 3 months ago - XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC - PRNewsWire